- Horizon CombinatoRx to perform drug combination screening on a lead oncology asset
Cambridge, UK 17 November 2014: Horizon Discovery Group plc (LSE:HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately USD $750,000 (GBP £469,000) for work to be completed within a five month period.
Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, Horizon CombinatoRx offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
Horizon completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014.
Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “We are delighted that Horizon CombinatoRx continues to gain the traction in the market we expected following the acquisition earlier this year. This latest contract with a top ten pharma in the oncology space continues to demonstrate the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”